# A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

> **NCT04773522** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab

## Key facts

- **NCT ID:** NCT04773522
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-10-14
- **Final completion:** 2025-09-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773522, "A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04773522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*